These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28280494)

  • 21. Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.
    Freitas EO; Nico D; Alves-Silva MV; Morrot A; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004297. PubMed ID: 26701750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.
    Costa LE; Chávez-Fumagalli MA; Martins VT; Duarte MC; Lage DP; Lima MI; Pereira NC; Soto M; Tavares CA; Goulart LR; Coelho EA
    Parasitology; 2015 Sep; 142(10):1335-47. PubMed ID: 26099574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.
    Ostolin TLVDP; Gusmão MR; Mathias FAS; Cardoso JMO; Roatt BM; Aguiar-Soares RDO; Ruiz JC; Resende DM; de Brito RCF; Reis AB
    Vaccine; 2021 May; 39(20):2755-2763. PubMed ID: 33875268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.
    Wang Q; Barry MA; Seid CA; Hudspeth EM; McAtee CP; Heffernan MJ
    J Biomed Mater Res B Appl Biomater; 2018 May; 106(4):1587-1594. PubMed ID: 28804955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Recombinant Chimeric Protein-Based Vaccine Containing T-Cell Epitopes from Amastigote Proteins and Combined with Distinct Adjuvants, Induces Immunogenicity and Protection against
    Lage DP; Vale DL; Linhares FP; Freitas CS; Machado AS; Cardoso JMO; de Oliveira D; Galvani NC; de Oliveira MP; Oliveira-da-Silva JA; Ramos FF; Tavares GSV; Ludolf F; Bandeira RS; Pereira IAG; Chávez-Fumagalli MA; Roatt BM; Machado-de-Ávila RA; Christodoulides M; Coelho EAF; Martins VT
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
    Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
    Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4
    de Franca MNF; Rodrigues LS; Barreto AS; da Cruz GS; Aragão-Santos JC; da Silva AM; de Jesus AR; Palatnik-de-Sousa CB; de Almeida RP; Corrêa CB
    Front Immunol; 2024; 15():1277557. PubMed ID: 38410517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites.
    Hofmeyer KA; Duthie MS; Laurance JD; Favila MA; Van Hoeven N; Coler RN; Reed SG
    Clin Vaccine Immunol; 2016 Sep; 23(9):785-94. PubMed ID: 27466350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40(-/-) C57BL/6 mice.
    Hernández Sanabria MX; Afonso LC; Golgher D; Tafuri WL; Vieira LQ
    Microbes Infect; 2007 Jul; 9(9):1124-34. PubMed ID: 17662634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Leishmania hypothetical protein-containing liposome-based formulation is highly immunogenic and induces protection against visceral leishmaniasis.
    Ribeiro PAF; Dias DS; Novais MVM; Lage DP; Tavares GSV; Mendonça DVC; Oliveira JS; Chávez-Fumagalli MA; Roatt BM; Duarte MC; Menezes-Souza D; Ludolf F; Tavares CAP; Oliveira MC; Coelho EAF
    Cytokine; 2018 Nov; 111():131-139. PubMed ID: 30142534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an immunogen containing CD4
    de Andrade Ferraz I; Carvalho AMRS; de Brito RCF; Roatt BM; Martins VT; Lage DP; Dos Reis Cruz L; Medeiros FAC; Gonçalves DU; da Costa Rocha MO; Coelho EAF; de Oliveira Mendes TA; Duarte MC; Menezes-Souza D
    Appl Microbiol Biotechnol; 2022 Jun; 106(12):4627-4641. PubMed ID: 35759035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
    Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
    Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.
    Chamakh-Ayari R; Bras-Gonçalves R; Bahi-Jaber N; Petitdidier E; Markikou-Ouni W; Aoun K; Moreno J; Carrillo E; Salotra P; Kaushal H; Negi NS; Arevalo J; Falconi-Agapito F; Privat A; Cruz M; Pagniez J; Papierok GM; Rhouma FB; Torres P; Lemesre JL; Chenik M; Meddeb-Garnaoui A
    PLoS One; 2014; 9(5):e92708. PubMed ID: 24786587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inoculation of the
    Soto M; Ramírez L; Solana JC; Cook ECL; Hernández-García E; Requena JM; Iborra S
    Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33673117
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.